BioSpace4d
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
appliedclinicaltrialsonline3d
Elevidys Shows Continued Promise in Phase III EMBARK Trial for the Treatment of Duchenne Muscular Dystrophy
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
BioSpace4d
5 DMD Candidates to Watch in 2025
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
The American Journal of Managed Care3d
EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
PepGen announces CONNECT program updates
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...
PMLiVE3d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
The American Journal of Managed Care7d
Prophylactic Cardiac Medication May Prolong Survival in DMD
Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals ...